Banner

What's New

Innovative resource for your improved understanding of
specialty diseases

Monthly Archives: October 2019

Hyper-targeting Oncologists

Whilst the importance of conferences such as ASCO and ASH are acknowledged this mantle is shared more than ever today.

ESMOs importance has grown significantly in recent years both in terms of size and diversity of audience as well as its reach as a global platform (e.g. more US healthcare professionals following ESMO online). In 2018, ESMO attracted nearly 28,000 attendees from 137 countries and over 3,000 submitted abstracts compared to 16,000 attendees from 127, and just over 2,000 submitted abstracts from the 2012 ESMO conference.

There has also been a noticeable rise in the importance of highly targeted disease-focused conferences such as EHA, IASLC, ICML, increased number of breakout meetings under the auspices of ASCO and ESMO (focusing on one cancer), and other similar scientific conferences with their increased importance as a platform for the dissemination of new data, meetings, exchange and reach to a global audience.

Hyper-targeting the right audience

With this in mind, biopharmaceutical companies need reliable agency partners with winning expertise and experience knowing what it takes to master these trends. In a highly competitive space where hyper-targeting is essential, MDoutlook provides clients with the right mix of agile assets, value solutions, and professional customer access to drive successful precision engagement with your most relevant customers in oncology, hematology, and rare diseases.

In a recent project, we measured the impact of our client’s new data announcements by interviewing oncologists in a rare disease area attending the International Congress on Malignant Lymphomas (ICML) in Lugano. The challenge was even greater due to the timing of the meeting, immediately following EHA and the need to engage oncologists based in the US and attending this highly focused European meeting.

Whether you are assessing the impact of data announcements or have another project in mind that requires hyper-targeting of your professional customers, we can enable your success by utilizing our proprietary assets and access to the world’s largest verified community of >120,000 treaters and experts in oncology, hematology, and rare diseases. This community is enriched through physician self-reported characteristics, and external adapters that are carefully and meaningfully applied through machine-learning and AI.

Meet us

We constantly deliver value to our clients by engaging the right professional customers to inform the clients’ business decisions and commercialization strategies of their assets in the right way throughout the product lifecycle.

Let’s take your next step together by arranging a meeting at your offices to scope out your future success!

For further discussion or to arrange a meeting, please contact [email protected] or call +1.404.496.4136.

The treatment landscape for prostate cancer is changing

Cabazitaxel was presented as an option for men with metastatic castration-resistant prostate cancer (mCRPC) who have progressed after treatment with docetaxel and an androgen signaling-targeted agent according to data presented at ESMO 2019.

The results showed a significant survival benefit for Cabazitaxel in third line over enzalutamide or abiraterone where patients had previously undergone treatment with one of the 2nd generation antiandrogens and docetaxel.

Impact of announcement

There was a general perception among prostate cancer ThoughtLeaders at ESMO 2019 that Cabazitaxel could become a new standard in mCRPC post-docetaxel and 2nd generation antiandrogen. Cabazitaxel is already widely available in many countries aiding the anticipated changes in treatment practices and guidelines. Contrary to current standard practices, switching to novel hormonal agents has been shown to be much less effective.

Our work with prostate cancer treating clinicians

Click to enlarge

Our work with prostate cancer treating clinicians (see slide for details of our track record and robust prostate cancer treating community) suggests that there will be some significant resistance to change treatment paradigms by cancer treaters especially amongst urologists. In past studies, cancer treaters were less likely to use chemotherapy due to perceived side effects and more likely to use novel hormonal agents despite the lack of supporting evidence especially in older patients. What is your take on the new data presented at ESMO 2019? Let’s set-up a call to further discuss.

Beyond prostate cancer, we offer rich experience, expertise and robust treaters and experts access in all solid, hematological & rare cancers.

Meet us

Let’s take your next step together by arranging a meeting at your offices to scope out your future success!

For further discussion or to arrange a meeting, please contact [email protected] or call +1.404.496.4136.

Driving impactful outcomes through precision intelligence

MDoutlook empowers confident business decisions with valuable precision insights and actionable intelligence.

At the recent 2019 annual meeting of the Association of Residents in Radiation Oncology (ASTRO), one of our clients was interested in recruiting very specific radiation oncologists (recruited to a very tight inclusion criteria) to an event at the congress to gain a richer understanding of their practices in a number of different tumor-areas and to collect real-world evidence (RWE). The interactive workshops proved highly successful and delivered a better understanding of the current practices of radiation-oncologists across indications to create value across functions (marketing, market access, and medical affairs).

We address client challenges across the product lifecycle and different business functions. During the conference season, for example, we are particularly busy helping clients gain valuable insight into their data presentations as well as measuring impact as can be seen from post-ASCO articles (clinical impact of ASCO presentations covering integration-of-new-treatment-regimens-in-CLL; novel-targeted-agents-for-MNSCLC and what-will-happen-in-NMCRPC and MHSPC.) published in partnership with OBR earlier this Summer.

MDoutlook drives maximizing the opportunity

We specialize in:

  • Connecting clients to the right treaters and experts through our validated community of 120,000 + treaters and 12,000+ experts.
  • Answering today’s critical business questions tomorrow via ONCpulse, our agile, adaptable and technology-driven solution.
  • Experience and expertise of our team that has won client praise and high satisfaction through offering hyper-personalized and impactful solutions.

Meet us

Let’s take your next step together by arranging a meeting at your offices to scope out your future success!

For further discussion or to arrange a meeting, please contact [email protected] or call +1 404.496.4136.